Birmingham, Alabama - OCM CLL Symposium by Carevive

Defining What is Value-Based Care for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: An Expert Roundtable Discussion

Saturday, November 4, 2017
8:30 am – 12:05 pm CST
UAB Comprehensive Cancer Center
Birmingham, Alabama

View Recording


Do the requirements of OCM and other value-based cancer delivery models leave you overwhelmed about where and how to start?

If so, then join us for a CME/CNE-Certified Symposium Featuring Key Experts in CLL as they discuss:

  • How value-based care models are transforming cancer care delivery in CLL
  • What are the evolving evidence-based approaches for personalized medical therapeutics and symptom management in relapsed/refractory CLL
  • How to incorporate geriatric risk assessment into the treatment decision-making process across the CLL care continuum
  • What are the challenges and successes of real world clinicians providing CLL care in a value-based care model environment

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western countries. In 2017, there will be an estimated 120,110 new cases of CLL diagnosed and an estimated 4,660 deaths (ACS, 2017). CLL is a chronic and incurable disease with the average patient receiving multiple lines of therapy throughout their disease course. The treatment goal of CLL is long-term remission and treatment depends on stage, risk status, and the patient’s overall health. Though CLL develops slowly, achieving long-term remission typically requires a combination of chemotherapy +/- immunotherapy and/or targeted therapies, and stem cell transplant for select high-risk recurrence patients. The number of people living with CLL in the United States is projected to increase 55% from 2011 to 2025 due to improved survival.

Providing better quality care for people with cancer (i.e., clinician performance) now drives reimbursement for cancer care services. Cancer centers and their hematologists face tremendous pressure in quantifiably delivering value in their care delivered. Thus, the question of how to deliver value-based CLL care is highly relevant.  While broad concepts are hypothesized to improve CLL care, the “science” of value-based cancer care is in its infancy. The association of quality metrics and patient outcomes are still largely a thing of the future—to be informed by pilot projects testing hypothesized high-quality, high value CLL care, such as the one proposed herein, and real-world evidence.

To support oncology providers in the era of value-based cancer care, Carevive Systems has worked with over 1,000 oncology experts to develop workflow and patient engagement tools that support the implementation of established oncology quality measurement programs and will aggregate longitudinal data tracking patients cared for under such delivery models.

Providers will participate in a, half-day, CME-accredited live symposium with CLL expert faculty to discuss the CLL treatment landscape and evolving principles and models of value-based care delivery in CLL care. Invitations are extended to all CLL providers and those interested in value-based cancer care to participate. Topics include a review of current evidence, case studies, and the intersection of quality measures, clinical CLL care, and strategies to implement value based cancer care.

Chair

Amitkumar Mehta, MD
University of Alabama

Faculty

Ashley Leak Bryant, PhD, RN-BC, OCN
University North Carolina Lineberger Comprehensive Cancer Center

Amy Goodrich, RN, BSN, MSN, CRNP-AC
Johns Hopkins Kimmel Cancer Center

Alberto Montero, MD, MBA, CPHQ
Taussig Cancer Center, Cleveland Clinic Foundation

Who Should Attend?

The target audiences for these activities are hematologists, medical oncologists, pulmonologists, pathologists, physician assistants, nurse practitioners, registered nurses, oncology nurses, nurse navigators, palliative/symptom management teams who care for patients with CLL and quality administrators responsible for their cancer center’s adherence to value-based care delivery models.


Learning Objectives

At the conclusion of this educational initiative, participants should be able to:

  • Apply new evidence-based guidelines for the diagnosis of CLL
  • Practice evidence-based guidelines to manage patients with relapsed/refractory CLL
  • Embed clinical workflow processes and IT infrastructure to standardize the symptom assessment and management of CLL patients
  • Employ a risk assessment model in clinical workflow to support treatment and surveillance planning for patients with relapsed/refractory CLL

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Carevive Systems, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 35 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 3.5 contact hours is provided by Postgraduate Institute for Medicine.

Designated for 0.8 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Disclosures

Amitkumar Mehta, MD Consulting Fees, BMS, Kite; Other, Gilead.

Ashley Leak Bryant PhD, RN-BC, OCN has no real or apparent conflicts of interest to report.

Amy Goodrich, RN, BSN, MSN, CRNP-AC Consulting Fees, Gilead.

Alberto Montero, MD, MBA, CPHQ Consulting Fees, Carevive Systems, Inc.

Planners and Managers

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Agenda

8:30 – 8:45 am CSTProgram OverviewAmit Mehta, MD (Chair)
University of Alabama (UAB)
8:45– 9:25 am CST (the last 10 minutes of each presentation reserved for Q&A)Introduction to MACRA and the Future of Value-Based Cancer CareAlberto Montero, MD, MBA
Taussig Cancer Center, Cleveland Clinic Foundation
9:25 – 10:05 am CSTAdvances in Treatment Planning for Relapsed/Refractory CLLAmit Mehta, MD (Chair)
10:05 – 10:45 am CSTCLL Risk Stratification ModelingAshley Leak Bryant, PhD, RN, OCN
University North Carolina Lineberger
10:45 am – 11:25 pm CSTStandardizing Symptom Assessment and Management in CLLAmy Goodrich, NP
Johns Hopkins Kimmel Cancer Center
11:25 – 12:05 pm CSTExpert Panel & Audience Discussion:  Determining What is Value-Based Care Delivery in CLLAll Faculty + UAB OCM Representative + Patient Perspective

This activity is supported by an independent educational grant from Genentech BioOncology. 

Jointly provided by Postgraduate Institute for Medicine and Carevive Systems Inc.
Postgraduate Institute for Medicine and Carevive Logos

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.